videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          id
        }
      }
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    title
    slug
    lang
    htmlBody
    ... on Video {
      imgUrl
      videoUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    id
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

first

order

upcoming

edges

Head of Equities

Michael Friis

ExpreS2ion Biotech Holding

ExpreS2ion Biotechnologies is expected to release its Q3 2024 results on 14 November 2024. Later the same day at 11:00, the company’s CEO Bent U. Frandsen and CFO Keith Alexander will take a deeper dive into the results and achievements during the period in an online live presentation. The management presentation will be followed by a Q&A session.

ExpreS2ion Biotechnologies is expected to release its Q3 2024 results on 14 November 2024. Later the same day at 11:00, the company&#x2019;s CEO Bent U. Frandsen and CFO Keith Alexander will take a deeper dive into the results and achievements during the period in an online live presentation. The management presentation will be followed by a Q&amp;A session. Besides the financial results and capital situation, further advancement in its development plans for its breast cancer candidate, ES2B-C001, could be in focus. Currently, the company has submitted a CTA application to the Austrian Agency for Health and Food Safety and is awaiting regulatory approval to commence the first-in-human phase I clinical trial. Furthermore, the latest development regarding its pipeline could come into focus. Looking at the recent news, ExpreS2ion Biotechnologies has announced that a term sheet has been entered with one of the largest vaccine manufacturers in the world, Serum Institute of India Private Limited (SIIPL). Upon the execution of a definitive agreement with mutually agreed-upon terms, SIIPL will obtain exclusive licensing rights to develop, manufacture, and commercialize certain malaria vaccine product lines, currently in phase I and phase II clinical development. ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system. Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 09.03 17 October 2024.

Pysy ajantasalla Inderesin uutiskirjeillä